Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michele Ferrara

Showing results (161-170 of 170) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 170 results.
Cancer Treatment Reviews|November 2, 2023
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle?Francesco Maria Venanzi, Marta Bini, Antonio Nuccio, et al.
Science Translational Medicine|June 3, 2021
Rebalancing expression of HMGB1 redox isoforms to counteract muscular dystrophyGiorgia Careccia, Marielle Saclier, Mario Tirone, et al.
Lung Cancer (Amsterdam, Netherlands)|January 3, 2025
Exploring machine learning tools in a retrospective case-study of patients with metastatic non-small cell lung cancer treated with first-line immunotherapy: A feasibility single-centre experienceFrancesca Rita Ogliari, Alberto Traverso, Simone Barbieri, et al.
Eclinicalmedicine|September 19, 2025
Impact of platinum-based chemotherapy and CTLA-4 inhibition on acquired resistance to first-line anti-PD-1/PD-L1 agents in non-small cell lung cancer: a systematic review and reconstructed individual patient data analysisSara Oresti, Fabio Salomone, Antonio Nuccio, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 21, 2025
Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi-Center Real-World StudyFederica Lo Prinzi, Federico Rossari, Antonio De Rosa, et al.
European Journal of Cancer (Oxford, England : 1990)|May 2, 2026
Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumabAndrea Casadei-Gardini, Terry Cheuk-Fung Yip, Alessandro Vitale, et al.
Cancer Treatment and Research Communications|March 9, 2026
A viable human lung cancer tissue collection (LCTC) to accelerate translational researchVirginia Guzzeloni, Alessandra Bartolucci, Samuele Valci, et al.
Targeted Oncology|February 27, 2026
Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and DurvalumabSilvia Camera, Lorenzo Fornaro, Margherita Rimini, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 12, 2025
Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International CentersMargherita Rimini, Lorenzo Fornaro, Masafumi Ikeda, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 17, 2025
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC-D IndexMara Persano, Margherita Rimini, Francesca Salani, et al.
Pageof 17

Showing results (161-170 of 170) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 170 results.
Cancer Treatment Reviews|November 2, 2023
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle?Francesco Maria Venanzi, Marta Bini, Antonio Nuccio, et al.
Science Translational Medicine|June 3, 2021
Rebalancing expression of HMGB1 redox isoforms to counteract muscular dystrophyGiorgia Careccia, Marielle Saclier, Mario Tirone, et al.
Lung Cancer (Amsterdam, Netherlands)|January 3, 2025
Exploring machine learning tools in a retrospective case-study of patients with metastatic non-small cell lung cancer treated with first-line immunotherapy: A feasibility single-centre experienceFrancesca Rita Ogliari, Alberto Traverso, Simone Barbieri, et al.
Eclinicalmedicine|September 19, 2025
Impact of platinum-based chemotherapy and CTLA-4 inhibition on acquired resistance to first-line anti-PD-1/PD-L1 agents in non-small cell lung cancer: a systematic review and reconstructed individual patient data analysisSara Oresti, Fabio Salomone, Antonio Nuccio, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 21, 2025
Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi-Center Real-World StudyFederica Lo Prinzi, Federico Rossari, Antonio De Rosa, et al.
European Journal of Cancer (Oxford, England : 1990)|May 2, 2026
Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumabAndrea Casadei-Gardini, Terry Cheuk-Fung Yip, Alessandro Vitale, et al.
Cancer Treatment and Research Communications|March 9, 2026
A viable human lung cancer tissue collection (LCTC) to accelerate translational researchVirginia Guzzeloni, Alessandra Bartolucci, Samuele Valci, et al.
Targeted Oncology|February 27, 2026
Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and DurvalumabSilvia Camera, Lorenzo Fornaro, Margherita Rimini, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 12, 2025
Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International CentersMargherita Rimini, Lorenzo Fornaro, Masafumi Ikeda, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 17, 2025
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC-D IndexMara Persano, Margherita Rimini, Francesca Salani, et al.
Pageof 17